NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
City of Hope Medical Center
Merck Sharp & Dohme LLC
Alaunos Therapeutics
Tempus AI
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Sichuan Enray Pharmaceutical Sciences Company
NGM Biopharmaceuticals, Inc
Elevation Oncology
Stanford University
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantCell, Inc.
NantCell, Inc.
ADC Therapeutics S.A.
Exelixis
Eli Lilly and Company
Pfizer
University Hospital, Ghent
pharmaand GmbH
Hoffmann-La Roche
Revolution Medicines, Inc.
Corcept Therapeutics
Five Prime Therapeutics, Inc.
Gilead Sciences
Novartis
National Institutes of Health Clinical Center (CC)
Ipsen
National Institutes of Health Clinical Center (CC)
Pfizer
Washington University School of Medicine
University of Kansas Medical Center
Roswell Park Cancer Institute
Amgen
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc